| Year |
Citation |
Score |
| 2023 |
Gross EG, Hamo MA, Estevez-Ordonez D, Laskay NM, Atchley TJ, Johnston JM, Markert JM. Oncolytic virotherapies for pediatric tumors. Expert Opinion On Biological Therapy. 1-17. PMID 37749907 DOI: 10.1080/14712598.2023.2245326 |
0.304 |
|
| 2022 |
Kang KD, Bernstock JD, Totsch SK, Gary SE, Rocco A, Nan L, Li R, Etminan T, Han X, Beierle EA, Eisemann T, Wechsler-Reya RJ, Bae S, Whitley R, Gillespie GY, ... Markert JM, et al. Safety and efficacy of intraventricular immunovirotherapy with oncolytic HSV-1 for CNS cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36239623 DOI: 10.1158/1078-0432.CCR-22-1382 |
0.306 |
|
| 2022 |
Ghajar-Rahimi G, Kang KD, Totsch SK, Gary S, Rocco A, Blitz S, Kachurak K, Chambers MR, Li R, Beierle EA, Bag A, Johnston JM, Markert JM, Bernstock JD, Friedman GK. Clinical advances in oncolytic virotherapy for pediatric brain tumors. Pharmacology & Therapeutics. 239: 108193. PMID 35487285 DOI: 10.1016/j.pharmthera.2022.108193 |
0.338 |
|
| 2022 |
Quinn CH, Beierle AM, Hutchins SC, Marayati R, Bownes LV, Stewart JE, Markert HR, Erwin MH, Aye JM, Yoon KJ, Friedman GK, Willey CD, Markert JM, Beierle EA. Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy. Cancers. 14. PMID 35159029 DOI: 10.3390/cancers14030762 |
0.301 |
|
| 2022 |
Miller KE, Cassady KA, Roth JC, Clements J, Schieffer KM, Leraas K, Miller AR, Prasad N, Leavenworth JW, Aban IB, Whitley RJ, Gillespie GY, Mardis ER, Markert JM. Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 28: 498-506. PMID 35105718 DOI: 10.1158/1078-0432.CCR-21-2636 |
0.316 |
|
| 2021 |
Friedman GK, Johnston JM, Bag AK, Bernstock JD, Li R, Aban I, Kachurak K, Nan L, Kang KD, Totsch S, Schlappi C, Martin AM, Pastakia D, McNall-Knapp R, Farouk Sait S, ... ... Markert JM, et al. Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas. The New England Journal of Medicine. PMID 33838625 DOI: 10.1056/NEJMoa2024947 |
0.32 |
|
| 2021 |
Kang K, Bernstock J, Mott B, Nan L, Li R, Totsch S, Gary S, Ghajar-Rahimi G, Etminan T, Eisemann T, Wechsler-Reya R, Beierle E, Gillespie G, Markert J, Friedman G. EPCT-22 SAFETY AND EFFICACY OF INTRAVENTRICULAR IMMUNOVIROTHERAPY WITH ONCOLYTIC HSV-1 G207 FOR TREATMENT OF LEPTOMENINGEAL DISEASE Neuro-Oncology. 23: i51-i52. DOI: 10.1093/neuonc/noab090.208 |
0.335 |
|
| 2020 |
Chambers MR, Bentley RT, Crossman DK, Foote JB, Koehler JW, Markert JM, Omar NB, Platt SR, Self DM, Shores A, Sorjonen DC, Waters AM, Yanke AB, Gillespie GY. The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas. Frontiers in Surgery. 7: 59. PMID 33005623 DOI: 10.3389/Fsurg.2020.00059 |
0.349 |
|
| 2020 |
Bastola S, Pavlyukov MS, Yamashita D, Ghosh S, Cho H, Kagaya N, Zhang Z, Minata M, Lee Y, Sadahiro H, Yamaguchi S, Komarova S, Yang E, Markert J, Nabors LB, et al. Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy. Nature Communications. 11: 4660. PMID 32938908 DOI: 10.1038/S41467-020-18189-Y |
0.404 |
|
| 2020 |
Bernstock JD, Bag A, Fiveash J, Kachurak K, Elsayed G, Chagoya G, Gessler F, Valdes PA, Madan-Swain A, Whitley R, Markert J, Gillespie Y, Johnston JM, Friedman GK. Design and Rationale for First-In-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors. Human Gene Therapy. PMID 32657154 DOI: 10.1089/Hum.2020.101 |
0.392 |
|
| 2019 |
Bernstock JD, Vicario N, Rong L, Valdes PA, Choi BD, Chen JA, DiToro D, Osorio DS, Kachurak K, Gessler F, Johnston JM, Atkinson TP, Whitley RJ, Bag AK, Gillespie GY, Markert JM, et al. A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition. Oncoimmunology. 8: e1678921. PMID 31741780 DOI: 10.1080/2162402X.2019.1678921 |
0.303 |
|
| 2019 |
Fathallah-Shaykh HM, DeAtkine A, Coffee E, Khayat E, Bag AK, Han X, Warren PP, Bredel M, Fiveash J, Markert J, Bouaynaya N, Nabors LB. Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study. Plos Medicine. 16: e1002810. PMID 31136584 DOI: 10.1371/Journal.Pmed.1002810 |
0.303 |
|
| 2019 |
Pearl TM, Markert JM, Cassady KA, Ghonime MG. Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors. Molecular Therapy Oncolytics. 13: 14-21. PMID 30997392 DOI: 10.1016/J.Omto.2019.03.001 |
0.317 |
|
| 2019 |
Yamashita D, Minata M, Yu H, Zhang S, Li C, Flanary V, Ghosh S, Lee Y, Cho H, Botta D, Guo X, Ozaki S, Yamaguchi S, Komarova S, Bastola S, ... ... Markert J, et al. TMIC-12. TUMOR EDGE-DESTINED CELLS IN GBM CELLS IN A CELL-INTRINSIC MECHANISM Neuro-Oncology. 21: vi249-vi249. DOI: 10.1093/Neuonc/Noz175.1046 |
0.43 |
|
| 2019 |
Cassady K, Miller K, Prasad N, Maric D, Bernstock J, Roth J, Barker N, Coleman J, Schieffer K, Leraas K, Miller A, Leavenworth J, Cutter G, Whitley R, Roizman B, ... ... Markert J, et al. ATIM-32. PREDICTORS OF IMPROVED SURVIVAL FOLLOWING ONCOLYTIC VIRUS TREATMENT IN PATIENTS WITH RECURRENT GLIOBLASTOMA: GENE EXPRESSION ANALYSIS FROM THE PHASE IB G207 CLINICAL TRIAL Neuro-Oncology. 21: vi8-vi8. DOI: 10.1093/Neuonc/Noz175.031 |
0.386 |
|
| 2018 |
Bernstock JD, Wright Z, Bag AK, Gessler F, Gillespie GY, Markert JM, Friedman GK, Johnston JM. Stereotactic Placement of Intratumoral Catheters for Continuous Infusion Delivery of HSV-1 G207 in Pediatric Malignant Supratentorial Brain Tumors. World Neurosurgery. PMID 30481622 DOI: 10.1016/J.Wneu.2018.11.122 |
0.321 |
|
| 2018 |
Friedman GK, Bernstock JD, Chen D, Nan L, Moore BP, Kelly VM, Youngblood SL, Langford CP, Han X, Ring EK, Beierle EA, Gillespie GY, Markert JM. Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. Scientific Reports. 8: 13930. PMID 30224769 DOI: 10.1038/S41598-018-32353-X |
0.349 |
|
| 2018 |
Yamashita D, Zhang S, Yu H, Sadahiro H, Yamaguchi S, Komarova S, Bastola S, Ghosh S, Ganguly A, Nabors B, Markert J, Yang Z, Zamboni N, Nakano I. Cbmt-41. Glioblastoma Clones Derived From Tumor Core And Edge Display Spatial Metabolic Heterogeneity Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.160 |
0.321 |
|
| 2018 |
Yu H, Pavlyukov MS, Minata M, Zhang S, Bastola S, Markert J, Bhat K, Wang M, Nakano I. Tmic-16. Core-Like Tumor Cells Promote Malignance Of Glioblastoma Via Intercellular Crosstalk With Edge-Like Tumor Cells In A Hdac1-Cd109 Dependent Manner Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.1075 |
0.379 |
|
| 2018 |
Friedman G, Bag A, Madan-Swain A, Li R, Kachurak K, Osorio D, Hukin J, Martin A, Pastakia D, Karajannis M, Bernstock J, Fiveash J, Reddy A, Whitley R, Gillespie Y, ... Markert J, et al. IMMU-08. PHASE I TRIAL (NCT02457845) SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF IMMUNOVIROTHERAPY WITH HSV G207 IN CHILDREN WITH PROGRESSIVE MALIGNANT SUPRATENTORIAL BRAIN TUMORS Neuro-Oncology. 20: i100-i100. DOI: 10.1093/Neuonc/Noy059.324 |
0.375 |
|
| 2017 |
Ghonime MG, Jackson J, Shah A, Roth J, Li M, Saunders U, Coleman J, Gillespie GY, Markert JM, Cassady KA. Chimeric HCMV/HSV-1 and Δγ134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory. Translational Oncology. 11: 86-93. PMID 29216507 DOI: 10.1016/J.Tranon.2017.10.005 |
0.318 |
|
| 2017 |
Waters AM, Johnston JM, Reddy AT, Fiveash J, Madan-Swain A, Kachurak K, Bag AK, Gillespie GY, Markert JM, Friedman GK. Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors. Human Gene Therapy. Clinical Development. 28: 7-16. PMID 28319448 DOI: 10.1089/Humc.2017.002 |
0.394 |
|
| 2017 |
Foreman PM, Friedman GK, Cassady KA, Markert JM. Oncolytic Virotherapy for the Treatment of Malignant Glioma. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 14: 333-344. PMID 28265902 DOI: 10.1007/S13311-017-0516-0 |
0.326 |
|
| 2017 |
Waters AM, Johnston JM, Reddy AT, Fiveash J, Madan-Swain A, Kachurak K, Bag AK, Gillespie GY, Markert JM, Friedman GK. Rationale and Design of a Phase I Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors. Human Gene Therapy. Clinical Development. PMID 28253733 DOI: 10.1089/hum.2017.002 |
0.394 |
|
| 2017 |
Rudnick JD, Fink KL, Landolfi JC, Markert J, Piccioni DE, Glantz MJ, Swanson SJ, Gringeri A, Yu J. Immunological targeting of CD133 in recurrent glioblastoma: A multi-center phase I translational and clinical study of autologous CD133 dendritic cell immunotherapy. Journal of Clinical Oncology. 35: 2059-2059. DOI: 10.1200/Jco.2017.35.15_Suppl.2059 |
0.41 |
|
| 2017 |
Bag A, Li R, Gillespie Y, Markert J, Johnston J, Friedman GK. Pdct-23. Proliferation Index Influences Initial Response Pattern Of Pediatric High-Grade Gliomas Treated With Hsv-1 G207 Oncolytic Virotherapy. Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.764 |
0.423 |
|
| 2016 |
Ring EK, Markert JM, Gillespie GY, Friedman GK. Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27836863 DOI: 10.1158/1078-0432.Ccr-16-1829 |
0.318 |
|
| 2016 |
Waters AM, Stafman LL, Garner EF, Mruthyunjayappa S, Stewart JE, Friedman GK, Coleman JM, Markert JM, Gillespie GY, Beierle EA. Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma. Translational Oncology. 9: 419-430. PMID 27751346 DOI: 10.1016/J.Tranon.2016.07.008 |
0.348 |
|
| 2016 |
Patel DM, Foreman PM, Nabors LB, Riley KO, Gillespie GY, Markert JM. Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. Human Gene Therapy. Clinical Development. 27: 69-78. PMID 27314913 DOI: 10.1089/humc.2016.031 |
0.341 |
|
| 2016 |
Patel D, Foreman P, Nabors B, Riley K, Gillespie Y, Markert J. Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. Human Gene Therapy. Clinical Development. PMID 27231756 DOI: 10.1089/hum.2016.031 |
0.341 |
|
| 2016 |
Ring E, Moore B, Nan L, Etminan T, Markert J, Gillespie GY, Friedman G. Pcm-21Expression Of Immune Checkpoint Proteins In Patient-Derived Pediatric Brain Tumor Xenografts Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now080.21 |
0.406 |
|
| 2016 |
Ring E, Moore B, Nan L, Etminan T, Markert J, Gillespie GY, Friedman G. Pcm-09Comparison Of The Sensitivities Of Pediatric High-Grade Brain Tumor Versus Adult Glioblastoma Xenografts To Engineered Oncolytic Herpes Simplex Virotherapy Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now080.09 |
0.373 |
|
| 2016 |
Reddy A, Johnston J, Madan-Swain A, Fiveash J, Bag A, Gillespie GY, Markert J, Friedman G. EPT-10PHASE I CLINICAL TRIAL OF HSV G207 ALONE OR WITH A SINGLE RADIATION DOSE IN CHILDREN WITH RECURRENT SUPRATENTORIAL BRAIN TUMORS (NCT02457845) Neuro-Oncology. 18: iii25.5-iii26. DOI: 10.1093/Neuonc/Now069.09 |
0.385 |
|
| 2015 |
Cripe TP, Chen CY, Denton NL, Haworth KB, Hutzen B, Leddon JL, Streby KA, Wang PY, Markert JM, Waters AM, Gillespie GY, Beierle EA, Friedman GK. Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children. Molecular Therapy Oncolytics. 2. PMID 26436135 DOI: 10.1038/Mto.2015.15 |
0.301 |
|
| 2015 |
Friedman GK, Beierle EA, Gillespie GY, Markert JM, Waters AM, Chen CY, Denton NL, Haworth KB, Hutzen B, Leddon JL, Streby KA, Wang PY, Cripe TP. Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children. Molecular Therapy Oncolytics. 2. PMID 26436134 DOI: 10.1038/Mto.2015.16 |
0.312 |
|
| 2015 |
Armstrong TS, Wen PY, Reardon DA, Phuphanich S, Aiken R, Landolfi JC, Curry WT, Zhu J, Glantz MJ, Peereboom DM, Markert J, LaRocca RV, O'Rourke D, Fink KL, Kim LJ, et al. Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107. Journal of Clinical Oncology. 33: 2036-2036. DOI: 10.1200/Jco.2015.33.15_Suppl.2036 |
0.339 |
|
| 2015 |
Wen P, Reardon D, Phuphanich S, Aiken R, Landolfi J, Curry W, Zhu J, Glantz M, Peereboom D, Markert J, Larocca R, O'Rourke D, Fink K, Kim L, Gruber M, et al. Imct-20Association Of Survival And Progression-Free Survival With Immune Response In Hla-A2+ Newly-Diagnosed Gbm Patients In Randomized Double-Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell (Dc) Immunotherapy With Ict-107 Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov218.20 |
0.34 |
|
| 2014 |
Clark GM, McDonald AM, Nabors LB, Fathalla-Shaykh H, Han X, Willey CD, Markert JM, Guthrie BL, Bredel M, Fiveash JB. Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: the University of Alabama at Birmingham experience. Neuro-Oncology Practice. 1: 172-177. PMID 26034629 DOI: 10.1093/Nop/Npu028 |
0.314 |
|
| 2014 |
Markert JM, Razdan SN, Kuo HC, Cantor A, Knoll A, Karrasch M, Nabors LB, Markiewicz M, Agee BS, Coleman JM, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Weichselbaum RR, et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1048-55. PMID 24572293 DOI: 10.1038/Mt.2014.22 |
0.308 |
|
| 2014 |
Megison ML, Gillory LA, Stewart JE, Nabers HC, Mroczek-Musulman E, Waters AM, Coleman JM, Kelly V, Markert JM, Gillespie GY, Friedman GK, Beierle EA. Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumors. Plos One. 9: e86843. PMID 24497984 DOI: 10.1371/Journal.Pone.0086843 |
0.307 |
|
| 2014 |
Wen PY, Reardon DA, Phuphanich S, Aiken R, Landolfi JC, Curry WT, Zhu J, Glantz MJ, Peereboom DM, Markert J, LaRocca RV, O'Rourke D, Fink KL, Kim LJ, Gruber ML, et al. A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients. Journal of Clinical Oncology. 32: 2005-2005. DOI: 10.1200/Jco.2014.32.15_Suppl.2005 |
0.405 |
|
| 2014 |
Wen P, Reardon D, Phuphanich S, Aiken R, Landolfi J, Curry W, Zhu J, Glantz M, Peereboom D, Markert J, Larocca R, O'Rourke D, Fink K, Kim L, Gruber M, et al. At-60A Randomized Double Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell (Dc) Vaccine Ict-107 Following Standard Treatment In Newly Diagnosed Patients With Gbm Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.59 |
0.355 |
|
| 2013 |
Gillory LA, Megison ML, Stewart JE, Mroczek-Musulman E, Nabers HC, Waters AM, Kelly V, Coleman JM, Markert JM, Gillespie GY, Friedman GK, Beierle EA. Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastoma. Plos One. 8: e77753. PMID 24130898 DOI: 10.1371/Journal.Pone.0077753 |
0.31 |
|
| 2013 |
Friedman GK, Raborn J, Kelly VM, Cassady KA, Markert JM, Gillespie GY. Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy. Frontiers in Oncology. 3: 28. PMID 23450706 DOI: 10.3389/Fonc.2013.00028 |
0.337 |
|
| 2012 |
Markert JM. The role of early resection vs biopsy in the management of low-grade gliomas. Jama. 308: 1918-9. PMID 23099540 DOI: 10.1001/Jama.2012.14523 |
0.314 |
|
| 2012 |
Hawkins ES, Aiken R, Chandler J, Fink KL, Glantz MJ, Grewal J, Gruber ML, Kesari S, Landolfi JC, LaRocca RV, Lesser GJ, Markert J, Mayer TM, O'Rourke D, Peereboom DM, et al. A randomized, double‑blind, controlled phase IIb study of the safety and efficacy of ICT‑107 in newly diagnosed patients with glioblastoma multiforme following resection and chemoradiation. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps2107 |
0.425 |
|
| 2009 |
Parker JN, Bauer DF, Cody JJ, Markert JM. Oncolytic viral therapy of malignant glioma. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 6: 558-69. PMID 19560745 DOI: 10.1016/J.Nurt.2009.04.011 |
0.327 |
|
| 2009 |
Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Gillespie GY. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 199-207. PMID 18957964 DOI: 10.1038/Mt.2008.228 |
0.353 |
|
| 2008 |
Forsyth P, Roldán G, George D, Wallace C, Palmer CA, Morris D, Cairncross G, Matthews MV, Markert J, Gillespie Y, Coffey M, Thompson B, Hamilton M. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 627-32. PMID 18253152 DOI: 10.1038/Sj.Mt.6300403 |
0.376 |
|
| 2007 |
Radbill AE, Reddy AT, Markert JM, Wyss JM, Pike MM, Akella NS, Bharara N, Gillespie GY. Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain. Journal of Neurovirology. 13: 118-29. PMID 17505980 DOI: 10.1080/13550280601187177 |
0.307 |
|
| 2007 |
Shah AC, Parker JN, Gillespie GY, Lakeman FD, Meleth S, Markert JM, Cassady KA. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses. Gene Therapy. 14: 1045-54. PMID 17429445 DOI: 10.1038/Sj.Gt.3302942 |
0.386 |
|
| 2007 |
Guffey MB, Parker JN, Luckett WS, Gillespie GY, Meleth S, Whitley RJ, Markert JM. Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. Cancer Gene Therapy. 14: 45-56. PMID 16990846 DOI: 10.1038/Sj.Cgt.7700978 |
0.336 |
|
| 2004 |
Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, Kracher J, Grossman SA, Fisher JD, Carson K, Rosenblum M, Mikkelsen T, Olson J, Markert J, Rosenfeld S, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 958-66. PMID 15509513 DOI: 10.1016/J.Ymthe.2004.07.021 |
0.35 |
|
| 2003 |
Markert J. Glioblastoma multiforme: introduction. Cancer Journal (Sudbury, Mass.). 9: 148. PMID 12952299 DOI: 10.1097/00130404-200305000-00002 |
0.454 |
|
| 1996 |
Andreansky SS, He B, Gillespie GY, Soroceanu L, Markert J, Chou J, Roizman B, Whitley RJ. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proceedings of the National Academy of Sciences of the United States of America. 93: 11313-8. PMID 8876132 DOI: 10.1073/Pnas.93.21.11313 |
0.399 |
|
| 1992 |
Markert JM, Coen DM, Malick A, Mineta T, Martuza RL. Expanded spectrum of viral therapy in the treatment of nervous system tumors. Journal of Neurosurgery. 77: 590-4. PMID 1326612 DOI: 10.3171/Jns.1992.77.4.0590 |
0.331 |
|
| Show low-probability matches. |